Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
EMD Serono |
---|---|
Information provided by: | EMD Serono |
ClinicalTrials.gov Identifier: | NCT00738205 |
This is an international, multicenter study involving children treated with Saizen®, a growth hormone, who will be trained to use easypod, a new electronic injector and will complete a questionnaire after 12 week of use.
Both children naïve to growth hormone and dissatisfied with their current injection device will be recruited.
Condition |
---|
Growth Hormone Deficiency Turner Syndrome Chronic Renal Failure Small for Gestational Age |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-Injector When Administering Saizen® Growth Hormone to Children With Growth Disorders |
Estimated Enrollment: | 630 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1 |
2 |
An international, multicenter cross-sectional study (Observatoire des pratiques médicales®) involving a cohort of children treated with Saizen®, a growth hormone.
The study does not require any changes to the usual medical management of these patients and should not be considered detrimental to their physical or psychological integrity. No specific procedures or examinations will be requested, nor does the protocol require any particular treatment or follow-up visits.
Ages Eligible for Study: | 2 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
315 Naïve patients & 315 experienced patients dissatisfied with their current device.
Inclusion Criteria:
Exclusion Criteria:
Contact: Monia Zignani, Pharm. D., Ph D. | monia.zignani@merckserono.net |
Switzerland | |
Local Medical Information | Recruiting |
Zug, Switzerland | |
Contact: Local Medical Information +41-41-747-0812 |
Study Director: | Clément Olivier, MD, LMCC | Merck Serono International S.A., an affiliate of Merck KGaA, Darmstadt, Germany |
Responsible Party: | Merck Serono International S.A., an affiliate of Merck KGaA, Darmstadt, Germany ( Monia Zignani, Pharm. D., Ph D. ) |
Study ID Numbers: | Easypod |
Study First Received: | August 19, 2008 |
Last Updated: | September 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00738205 |
Health Authority: | Italy: Ethics Committee |
Electronic device Growth hormone treatment |
Chromosomal abnormalities Bone Diseases, Endocrine Dwarfism Hypopituitary dwarfism Renal Insufficiency Genital dwarfism Gonadal Disorders Kidney Failure, Chronic Dwarfism, Pituitary Brain Diseases Bone Diseases Sex Differentiation Disorders Gonadal dysgenesis Urogenital Abnormalities Hypopituitarism |
Musculoskeletal Diseases Urologic Diseases Bone Diseases, Developmental Kidney Diseases Congenital Abnormalities Hypothalamic Diseases Pituitary Diseases Chromosome Disorders Central Nervous System Diseases Endocrine System Diseases Growth hormone deficiency Monosomy X Turner Syndrome Genetic Diseases, Inborn Renal Insufficiency, Chronic |
Pathologic Processes Disease Syndrome Nervous System Diseases Sex Chromosome Disorders |